



SUVEN
LIFE SCIENCES LIMITED



Unwavering Purpose

SUVEN
LIFE SCIENCES LIMITED
BUSINESS RESPONSIBILITY REPORT
[Under Regulation 34(2)(f)]
2021-22



ABOUT THIS REPORT

The reporting framework used in this report is based on the 'National Voluntary Guidelines on Social, Environmental and Economic Responsibilities of Business (NVGs)' released by the Ministry of Corporate Affairs, Government of India, in July 2011, which contains 9 Principles and Core Elements for each of the Nine Principles.

This is Suven's fifth Business Responsibility Report. This report is intended to transparently disclose our performance based on the principles provided in the NVGs and is meant for all our stakeholders. We welcome your thoughts, comments and feedback as this will allow us to improve on our reporting and disclosure standards.

If you would like to send us feedback about this report, please email to investorservices@suven.com.

DISCLOSURES ON THE NINE PRINCIPLES AS CHARTED BY THE MINISTRY OF CORPORATE AFFAIRS IN THE "NATIONAL VOLUNTARY GUIDELINES (NVG) ON SOCIAL, ENVIRONMENTAL AND ECONOMIC RESPONSIBILITIES OF BUSINESS".

PRINCIPLE 1

Ethics Transparency & Accountability

Businesses should conduct and govern themselves with Ethics, Transparency and Accountability.

PRINCIPLE 2

Product Life Cycle Sustainability

Businesses should provide goods and services that are safe and contribute to sustainability throughout their lifecycle.

PRINCIPLE 3

Employee Well-Being

Businesses should promote the well-being of all employees.

PRINCIPLE 4

Stakeholder Engagement

Businesses should respect the interests of and be responsive towards all stakeholders, especially those who are disadvantaged, vulnerable and marginalised.

PRINCIPLE 5

Human Rights

Businesses should respect and promote human rights.

PRINCIPLE 6

Environment

Businesses should respect, protect and make efforts to restore the environment.

PRINCIPLE 7

Policy Advocacy

Businesses, when engaged in influencing public regulatory policy, should do so in a responsible manner.

PRINCIPLE 8

Inclusive Growth and Equitable Development

Businesses should support inclusive growth and equitable development.

PRINCIPLE 9

Customer Value

Businesses should engage with and provide value to their customers and consumers in a responsible manner.



From the Chairman's desk

“Medicine is the science of uncertainty and the art of probability, especially in our domain of work. **Given our unwavering Purpose and unrelenting spirit, we are confident of crossing the finishing line.**”



Venkateswarlu Jasti
Chairman & CEO

Dear Shareholders,

I trust you are safe and are continuing with the necessary precautions. For even as I share my thoughts with you, the number of covid positive cases have jumped sharply. We all need to come together once again to avoid another mayhem, of the likes we endured in the second wave.

FY22 has been a year of sustained effort in moving our molecules forward along the development journey.

Our lead molecules have progressed in their clinical journey. We have completed the Phase 2 study on Alzheimer's in the US for SUVN-502 (Masupirdine) but unfortunately it did not

meet the primary end point but has a great safety profile. Based on the promising secondary end point and safety profile and with the discussion with US FDA we will move this compound into Phase 3 clinical trial targeting agitation and aggression in Alzheimer type dementia and are initiating this Phase 3 study in North America and Europe.

SUVN-G3031 (Samelisant) undergoing Phase-2 study on Narcolepsy in North America, gained momentum during the year under review after the temporary slowdown owing to the pandemic. So far 130 patients have been randomized, of which 98 completed.

Our other two molecules are also ready for going through the Phase 2 PoC studies which should commence in the near future. Our hard work is germinating, nice and steady.

We have expended ₹106.37 Crores during FY 22 in development and clinical trials. We earned ₹11.84 Crores from Drug Discovery Services (assisting other innovators in their search for better medication). We reported consolidated Net Loss of ₹122 Crores.

Normally, a loss of this magnitude would lead entrepreneurs to rethink their strategy, realign their business model or maybe switch business spaces. Being discovery and development driven with high burning rate, the loss is bound to be there until we reach the stage of monetization/ commercialization after success in clinical development programs.

But for us, a loss is like our shadow. It can be at the very next step. But that does not prevent us from taking that step and many other such steps, which we have faithfully done over the last 19 years of our innovation journey.

Ours is a journey with a vision that is focused on providing solution to global unmet medical

needs. We have set on a course that is seldom the mainstream, yet capable of breaking the glass ceiling of the pharma sector. We are in these spaces because when barriers are high, the thrill of journeying past them is even higher and the satisfaction of overcoming them is far more intense. It drives us.

What we do will leave an indelible mark in our world of pharmaceutical innovation. When we succeed, we will leave behind a legacy that will improve the quality of life for millions across the world. When we don't meet the primary endpoint, we leave behind loads of data for like-minded innovators like us – to better what we have done. Both ways it's a win-win.

What's overtly aspiring for us is to continue with our innovative struggle to achieve that EUREKA moment, which can emerge as a beacon of hope for patients and their caregivers who are stuck in the quagmire of hopelessness.

The future looks just like what we perceived, a lot of it is in an exciting stage. Standing at a crucial juncture with 7 molecules in the clinical phase of the development journey, funding our future journey is critical to consolidating the foothold of the Company. I have

already funded ₹147 Crores but that itself is not enough. Hence, we are in the process of raising more funds through a rights issue which will help continue funding the development of our robust pipeline of molecules. Hopefully, our clinical molecules will generate sufficient global interest over the near to medium term.

We are committed to our innovation blueprint. We believe that progress is not a one-act play, it should be like a chain reaction - continuous and sustaining. This is the gospel of truth for us at SUVEN Life Sciences. Given our unwavering focus and unrelenting spirit, we are confident of crossing the finishing line.

I take this opportunity to express my sincere gratitude to my fellow Directors and employees for their commitment to strengthening our innovation ecosystem, ethical standards, and governance framework. I thank our esteemed shareholders, partners, and all stakeholders for believing in our vision and reaffirming confidence in our capability and brushing shoulders with us in our long but progressive journey.

Warm regards

Venkateswarlu Jasti
Chairman & CEO



SECTION A

GENERAL INFORMATION ABOUT THE COMPANY

1.	Corporate Identity Number (CIN) of the Company	L24110TG1989PLC009713
2.	Name of the Company	SUVEN LIFE SCIENCES LIMITED
3.	Registered address	8-2-334 I SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad – 500 034, Telangana, India
4.	Website	www.suven.com
5.	E-mail id	investorservices@suven.com
6.	Financial Year reported	April 2021 to March 2022
7.	Sector(s) that the Company is engaged in (industrial activity code-wise)	Pharmaceuticals
8.	List three key products/ services that the Company manufactures/ provides (as in balance sheet)	The Company is a research-focused organisation. As such, it does not have any product for marketing. The Company provide research services to global pharma/life sciences entities.
9.	Total number of locations where business activity is undertaken by the Company	Two R&D facilities at Jeedimetla and Pashamylaram in Telangana.
(a).	Number of International Locations (Provide details of major 5)	One Clinical Development Centre through our wholly-owned subsidiary in New Jersey.
(b).	Number of National Locations	Two R&D centers
10.	Markets served by the Company – Local/ State/ National/ International	Refer to segment report on page no. 125.

SECTION B

FINANCIAL DETAILS OF THE COMPANY

1.	Paid up Capital (INR)	₹1453.82 lakhs
2.	Revenue (INR) (standalone)	₹1184.43 lakhs (as on 31st March, 2022)
3.	Net Profit/(Loss) for the year (INR) (standalone)	₹(3624.86) lakhs (as on 31st March, 2022)
4.	Total Spending on Corporate Social Responsibility (CSR) as percentage of profit after tax (%)	Nil
5.	List of activities in which expenditure in 4 above has been incurred:-	NA

SECTION C

OTHER DETAILS

1.	Does the Company have any Subsidiary Company/ Companies?	Yes
2.	Do the Subsidiary Company/ Companies participate in the BR Initiatives of the parent company? If yes, then indicate the number of such subsidiary company(s)	No
3.	Do any other entity/ entities (e.g. suppliers, distributors etc.) that the Company does business with, participate in the BR initiatives of the Company? If yes, then indicate the percentage of such entity/ entities? [Less than 30%, 30-60%, More than 60%]	No



SECTION D

BR INFORMATION

1. Details of Director/Directors responsible for BR

(a) Details of the Director/Director responsible for implementation of the BR policy/policies

1.	DIN Number	00278028
2.	Name	Venkateswarlu Jasti
3.	Designation	Chairman & CEO

(b) Details of the BR head

No.	Particulars	Details
1.	DIN Number (if applicable)	00278028
2.	Name	Venkateswarlu Jasti
3.	Telephone number	040-23541142
4.	e-mail id	info@suvenc.com

2. Principle-wise (as per NVGs) BR Policy/policies

(a) Details of compliance (Reply in Y/N)

No.	Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8
1.	Do you have a policy/ policies for....	Yes							
2.	Has the policy being formulated in consultation with the relevant stakeholders?	Yes							
3.	Does the policy conform to any national/ international standards? If yes, specify? (50 words)	Yes							
4.	Has the policy being approved by the Board? Is yes, has it been signed by MD/ owner/ CEO/ appropriate Board Director?	Yes							
5.	Does the Company have a specified committee of the Board/ Director/ Official to oversee the implementation of the policy?	Yes							
6.	Indicate the link for the policy to be viewed online?	#	#	#	#	#	#	#	#
7.	Has the policy been formally communicated to all relevant internal and external stakeholders?	Yes							
8.	Does the Company have a grievance redressal mechanism related to the policy/ policies to address stakeholders' grievances related to the policy/ policies?	Yes							
9.	Has the Company carried out independent audit/ evaluation of the working of this policy by an internal or external agency?	Yes							

Details of information and links provided below.

P1: Refer to Whistle Blower Policy and Code of Conduct and Ethics P2: Available on our intranet P3: Available on our intranet P4: Refer to the CSR Policy (available on www.suven.com) and Sustainability Policy available on intranet P5: Available on our intranet P6: Available on our intranet P7: Available on our intranet P8: Refer to the CSR committee charter, CSR Policy (available on www.suven.com) and Sustainability Policy available on intranet P9: Available on our intranet.



(b) If answer to the question at serial number 1 against any principle, is 'No', please explain why:
(Tick up to 2 options)

No.	Questions	P 1	P 2	P 3	P 4	P 5	P 6	P 7	P 8
1.	The company has not understood the Principles								
2.	The company is not at a stage where it finds itself in a position to formulate and implement the policies on specified principles	Not applicable							
3.	The company does not have financial or manpower resources available for the task								
4.	It is planned to be done within next 6 months								
5.	It is planned to be done within the next 1 year								
6.	Any other reason (please specify)								

3. Governance related to BR

1.	Indicate the frequency with which the Board of Directors, Committee of the Board or CEO to assess the BR performance of the Company. Within 3 months, 3-6 months, Annually, More than 1 year	We have constituted a Corporate Social Responsibility (CSR) committee of the Board which oversees our CSR activities. The Committee meets once in year to assess the BR performance and align strategies in line with external realities.
2.	Does the Company publish a BR or a Sustainability Report? What is the hyperlink for viewing this report? How frequently it is published?	The Company publishes a BR and a Sustainability Report annually. Our Sustainability Report can be viewed at http:// www.suven.com/annual-reports.html



SECTION E

PRINCIPLE-WISE PERFORMANCE

Principle 1

1. Does the policy relating to ethics, bribery and corruption cover only the Company? Yes/ No. Does it extend to the Group/Joint Ventures/ Suppliers/ Contractors/ NGOs /Others?

Our policies on ethics, bribery and corruption cover the Company, its subsidiaries and branches and our suppliers and contractors.

2. How many stakeholder complaints have been received in the past financial year and what percentage was satisfactorily resolved by the management? If so, provide details thereof, in about 50 words or so.

Suven's stakeholders include investors, employees, customers, suppliers, contractors, bankers and financial institutions, government agencies and the local community. For details of Shareholders complaints, please refer to the Investors section in our Annual Report 2021-22.

Principle 2

1. List up to 3 of your products or services whose design has incorporated social or environmental concerns, risks and/or opportunities.

(a). Being research and development company, Suven Life Sciences offers analytical and technology services.

2. For each such product, provide the following details in respect of resource use (energy, water, raw material etc.) per unit of product (optional):

(a). Reduction during sourcing/ production/ distribution achieved since the previous year throughout the value chain?

Suven is into the niche area of NCE development. Under NCE development, materials (primarily chemicals and additives) required

vary widely. Since these are research projects, there is no defined standard for material procurement or quantum of usage. Hence, measuring reduction during sourcing does not seem to be not an appropriate efficiency benchmark for the Company.

(b). Reduction during usage by consumers (energy, water) has been achieved since the previous year?

Suven's innovation-focused business leverages its knowledge and skill to develops New Chemical Entities (NCEs) that address CNS-related ailments. Hence there is no specific standard for consumption of utilities namely energy, water etc. As a result, measuring the quantum of reduction in utilities is not relevant for the Company. Despite this reality, the Company, at its labs, adheres to systems and processes that are approved by globally respected and reputed regulatory authorities – this ensures that the consumption of utilities is optimised. Further, disciplined operations and real time monitoring of every process in its labs helps in reducing wastages.

3. Does the Company have procedures in place for sustainable sourcing (including transportation)?

Yes. At Suven, we have defined processes for addressing all sustainable sourcing of all key elements required in our business operations.

(a). If yes, what percentage of your inputs was sourced sustainably? Also, provide details thereof, in about 50 words or so.

We continuously strive to maintain the best practices for sustainable sourcing (number of partners: around 60). To ensure the seamless availability of all critical resources, we continue to identify alternate sources which ensures business continuity.

4. Has the Company taken any steps to procure goods and services from local & small producers, including communities surrounding their place of work?

Yes.

(a) If yes, what steps have been taken to improve their capacity and capability of local and small vendors?

The Company strives to improve the business of its vendors. It provides technical inputs to small vendors for improving product quality and operational efficiency. The company periodically informs small vendors of its innovation plans to enable them to align their products/intermediates/ reagents with the Company's innovation aspirations.

5. Does the Company have a mechanism to recycle products and waste? If yes what is the percentage of recycling of products and waste (separately as <5%, 5-10%, >10%). Also, provide details thereof, in about 50 words or so.

Suven is primarily into research and development of New Chemical Entities. As such, its operating infrastructure comprises R&D labs. As such its operations do not pose a significant burden on the environment. But, as an Earth-respecting corporate, the Company remains vigilant on its resource utilisation. Moreover, stringent adherence to globally-accepted lab processes ensures that its operations remain safe and waste-generation is minimised.

As a quality-focused organisation, the Company does not reprocess products which have failed the quality test. However, incidents of quality failure of products are rare and insignificant.



Principle 3

1.	Please indicate the Total number of employees.	We have 117 employees as on 31 March 2022.
2.	Please indicate the Total number of employees hired on temporary/ contractual/ casual basis.	We have 11 casual employees on contract as on 31 March 2022.
3.	Please indicate the Number of permanent women employees.	We have 32 women employees as on 31 March 2022.
4.	Please indicate the Number of permanent employees with disabilities	NIL
5.	Do you have an employee association that is recognised by management	The Company does not have an employee association
6.	What percentage of your permanent employees is members of this recognised employee association?	NA
7.	Please indicate the Number of complaints relating to child labour, forced labour, involuntary labour, sexual harassment in the last financial year and pending, as on the end of the financial year.	NIL

	Category	No of complaints filed during the financial year	No of complaints pending as on end of the financial year
1	Child labour/forced labour/involuntary labour	NIL	NIL
2	Sexual harassment	NIL	NIL
3	Discriminatory employment	NIL	NIL

8	What percentage of your under mentioned employees were given safety & skill up- gradation training in the last year?	Being a research-based organisation, Suven continuously focuses on enhancing the intellectual capital of its people by providing training on various technical aspects and on behavioral skills for all round development of its team. In addition, the Company also works on enhancing the awareness of its team on people-critical issues such safety and health.
	(a) Permanent Employees	(a) Nil
	(b) Permanent Women Employees	
	(c) Casual/Temporary/Contractual Employees	Nil
	(d) Employees with Disabilities	Nil

Principle 4

1	Has the Company mapped its internal and external stakeholders? Yes/No.	Yes, we have mapped our internal and external stakeholders.
2.	Out of the above, has the Company identified the disadvantaged, vulnerable & marginalised stakeholders	Yes, we have identified disadvantaged, vulnerable & marginalised stakeholders.
3	Are there any special initiatives taken by the Company to engage with the disadvantaged, vulnerable and marginalised stakeholders? If so, provide details thereof, in about 50 words or so.	No, during the year the Company did not have any opportunity of dealing with disadvantaged, vulnerable and marginalised stakeholders.

Principle 5

1.	Does the policy of the Company on human rights cover only the Company or extend to the Group/ Joint Ventures/ Suppliers/ Contractors/ NGOs/ Others?	At present, our policy is extended to the group, our suppliers, contractors and NGOs.
2.	How many stakeholder complaints have been received in the past financial year and what percent was satisfactorily resolved by the management?	We did not receive any complaints in the last financial year.

Principle 6

1	Does the policy related to Principle 6 cover only the Company or extends to the Group/ Joint Ventures/ Suppliers/ Contractors/ NGOs/ others.	The policy at present covers the Company, its subsidiary and branches.
2	Does the Company have strategies/ initiatives to address global environmental issues such as climate change, global warming, etc.? Y/N. If yes, please give hyperlink for webpage etc.	The Company firmly believes that every organisation must endeavour to reduce its load on the Earth to make the world a better place. In keeping with this philosophy, the Company continues to invest in energy-efficient equipment and alter processes to optimise consumption of utilities (air, water and energy) and minimise noise pollution – thereby minimising its carbon footprint.
3	(c) Casual/Temporary/Contractual Employees	Yes.
4	Does the Company have any project related to Clean Development Mechanism? If so, provide details thereof, in about 50 words or so. Also, if yes, whether any environmental compliance report is filed?	At present, the Company does not have any project related to Clean Development Mechanism.
5	Has the Company undertaken any other initiatives on – clean technology, energy efficiency, renewable energy, etc. Y/N. If yes, please give hyperlink for web page etc.	No
6	Are the Emissions/ Waste generated by the Company within the permissible limits given by CPCB/ SPCB for the financial year being reported?	Yes
7	Number of show cause/ legal notices received from CPCB/ SPCB which are pending (i.e. not resolved to satisfaction) as on end of Financial Year.	None.





Principle 7

1. **Is your company a member of any trade and chamber or association? If Yes, Name only those major ones that your business deals with:**
 - a. (a) Pharmaceutical Export Promotion Council
 - b. (b) Bulk Drugs Manufacturers Association
 - c. (c) Telangana Government Pharmaceutical Task Force
2. **Have you advocated/ lobbied through above associations for the advancement or improvement of public good? Yes/No; if yes specify the broad areas (drop box: Governance and Administration, Economic Reforms, Inclusive Development Policies, Energy security, Water, Food Security, Sustainable Business Principles, Others)**
 Yes. The Company's Chairman represented Pharmaceutical companies to the Government of India and central policy making bodies in suggesting reforms and development policies for innovative research programs and providing encouragement and incentives for innovation and improvement.

Principle 8

1. **Does the Company have specified programmes/ initiatives/ projects in pursuit of the policy related to Principle 8? If yes details thereof.**
 There is no CSR obligation on Suven Life Sciences (post-demerger), hence there were no community development projects undertaken by the Company.
2. **Are the programmes/ projects undertaken through in-house team/ own foundation/ external NGO/ government structures/ any other organisation?**
 N.A.
3. **Have you done any impact assessment of your initiative?**
 N.A.
4. **What is your company's direct contribution to community development projects- Amount in INR and the details of the projects undertaken?**
 There is no CSR obligation on Suven Life Sciences (post-demerger), hence no money was spent on community development projects.

5. **Have you taken steps to ensure that this community development initiative is successfully adopted by the community? Please explain in 50 words, or so.**
 Since there were no community development initiatives funded or undertaken by the Company, this does not apply to the Company.

Principle 9

1. **What percentage of customer complaints/ consumer cases are pending as on the end of financial year?**
 Nil
2. **Does the Company display product information on the product label, over and above what is mandated as per local laws? Yes/No/N.A. /Remarks (additional information)**
 Yes.
3. **Is there any case filed by any stakeholder against the Company regarding unfair trade practices, irresponsible advertising and/ or anticompetitive behaviour during the last five years and pending as on end of financial year? If so, provide details thereof, in about 50 words or so.**
 No. Investor complaints as and when received are addressed immediately and the status of such complaints is provided as part of the Annual Report.
4. **Did your company carry out any consumer survey/ consumer satisfaction trends?**
 No. As the Company's products are not intended for direct consumption by consumers.





**SUVEN
LIFE SCIENCES LIMITED**

CIN: L24110TG1989PLC009713
SDE SERENE CHAMBERS
ROAD NO. 5, AVENUE 7
BANJARA HILLS
HYDERABAD - 500 034
TELANGANA